Drugs / Xuezhikang
Xuezhikang
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02603770 | Nov 2015 → Jan 2016 | inherited lipid metabolism disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01327014 | Apr 2011 → Dec 2012 | hyperlipidemia | Beijing Peking University WBL Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06750783 | Dec 2024 → Mar 2026 overdue | prediabetes syndrome | Beijing Tsinghua Chang Gung Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05238012 | Aug 2022 → Apr 2024 | glucose metabolism disease | Heart Health Research Center | Completed | No outcome recorded |
| Phase 4 | NCT01686451 | Aug 2012 → Sep 2013 | hyperlipidemia | Wenzhou Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02057302 | Mar 2010 → Dec 2012 | hyperlipidemia | China Academy of Chinese Medical Sciences | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05976893 Background | Aug 2023 → Dec 2025 | atherosclerotic cardiovascular disease, cancer | Xiang Xie | Unknown | No outcome recorded |
| Phase 4 | NCT02254824 Comparator | Oct 2013 → Oct 2015 | hypertensive disorder | Chinese Academy of Medical Sciences, Fuwai Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XueZhiKang | “The moderate intensity statins used during the study are one of atorvastatin 10-20mg qd, resuvastatin 5-10mg qd, and xuezhikang 0.6g bid (statin intolerance).” NCT05976893 ↗ |
| Known as | Xuezhikang Capsule | “Xuezhikang Capsule, specification: 300mg / capsule.” NCT05238012 ↗ |
| Known as | XZK | “XZK, a partially purified red yeast rice (RYR) under controlled pharmaceutical manufacturing conditions, contains a family of naturally occurring statins (monacolins)-most...” NCT05238012 ↗1“XueZhiKang (XZK), a botanic product with multiple components” NCT01327014 ↗ |
| Action | Activate | “XZK can also activate the PPARα pathway and up-regulate apolipoprotein A5” NCT05238012 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “a botanic product with multiple components” NCT01327014 ↗ |
| Route | Oral | “Patients in this group will take 2 capsules of Xuezhikang every time, twice every day, respectively after breakfast and supper.” NCT02057302 ↗ |